A detailed history of Lynx1 Capital Management LP transactions in Passage Bio, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 8,426,955 shares of PASG stock, worth $5.48 Million. This represents 2.11% of its overall portfolio holdings.

Number of Shares
8,426,955
Holding current value
$5.48 Million
% of portfolio
2.11%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.64 - $1.0 $5.39 Million - $8.43 Million
8,426,955 New
8,426,955 $5.9 Million
Q2 2024

Aug 14, 2024

BUY
$0.79 - $1.58 $4 Million - $7.99 Million
5,057,629 New
5,057,629 $4 Million
Q1 2024

May 15, 2024

BUY
$0.86 - $1.73 $3.84 Million - $7.73 Million
4,466,712 Added 1178.06%
4,845,871 $6.54 Million
Q4 2023

Feb 14, 2024

BUY
$0.6 - $1.01 $113,421 - $190,925
189,035 Added 99.43%
379,159 $382,000
Q3 2023

Nov 14, 2023

SELL
$0.66 - $1.01 $644,964 - $986,991
-977,219 Reduced 83.71%
190,124 $125,000
Q2 2023

Aug 14, 2023

SELL
$0.82 - $1.19 $1.84 Million - $2.67 Million
-2,240,255 Reduced 65.74%
1,167,343 $1.1 Million
Q1 2023

May 15, 2023

BUY
$0.96 - $1.88 $49,613 - $97,160
51,681 Added 1.54%
3,407,598 $3.27 Million
Q4 2022

Feb 14, 2023

BUY
$1.06 - $1.48 $639,704 - $893,172
603,495 Added 21.93%
3,355,917 $4.63 Million
Q3 2022

Nov 14, 2022

BUY
$1.22 - $2.48 $2.84 Million - $5.78 Million
2,331,012 Added 553.15%
2,752,422 $3.44 Million
Q2 2022

Aug 15, 2022

BUY
$1.63 - $3.46 $514,926 - $1.09 Million
315,906 Added 299.43%
421,410 $995,000
Q1 2022

May 16, 2022

BUY
$2.66 - $6.49 $280,640 - $684,720
105,504 New
105,504 $327,000

Others Institutions Holding PASG

About Passage BIO, Inc.


  • Ticker PASG
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,463,200
  • Market Cap $35.4M
  • Description
  • Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...
More about PASG
Track This Portfolio

Track Lynx1 Capital Management LP Portfolio

Follow Lynx1 Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lynx1 Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Lynx1 Capital Management LP with notifications on news.